Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.
BACKGROUND
Gefitinib remains an excellent treatment option for patients with a variety of cancers, including non small cell lung cancer (NSCLC). However, clinicians must be aware of the potential of gefitinib to cause an inflammatory reaction in the skin, lungs and bladder.


METHODS
We present a case on hemorrhagic cystitis and severely contracted bladder in a patient with NSCLC on gefitinib.


CONCLUSIONS
Further studies are needed to substantiate the association of gefitinib therapy with hemorrhagic cystitis and contracted bladder.
Arakawa
Maki
M
Department of Urology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan.
Nakamura
Kogenta
K
Yamada
Yoshiaki
Y
Rosser
Charles J
CJ
Tobiume
Motoi
M
Saito
Hiroko
H
Hasegawa
Takaaki
T
Honda
Nobuaki
N
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003556:Cystitis / Q000139:chemically induced* / Q000175:diagnosis*; D000077156:Gefitinib; D006417:Hematuria / Q000139:chemically induced* / Q000175:diagnosis*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D001745:Urinary Bladder Diseases / Q000139:chemically induced* / Q000175:diagnosis*
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib